| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Common Stock | Sale | -$28.5K | -300 | -0.79% | $95.00 | 37.9K | Mar 18, 2022 | Direct | F1 |
| transaction | NBIX | Common Stock | Sale | -$804K | -8.46K | -22.34% | $95.05 | 29.4K | Mar 22, 2022 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. |
| F2 | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F3 | Includes an aggregate of 39 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |